A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance

References

• Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707–20. doi:10.1016/j.cell.2017.01.017.
   PubMed Web of Science ®Google Scholar
• Marin-Acevedo JA, Kimbrough EO, Lou Y. Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol. 2021;14(1):45. doi:10.1186/s13045-021-01056-8.
   PubMed Web of Science ®Google Scholar
• Santiago-Sanchez GS, Hodge JW, Fabian KP. Tipping the scales: immunotherapeutic strategies that disrupt immunosuppression and promote immune activation. Front Immunol. 2022;13:993624. doi:10.3389/fimmu.2022.993624.
   PubMed Web of Science ®Google Scholar
• McDermott D, Haanen J, Chen TT, Lorigan P, O’Day S, investigators MDX. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol. 2013;24(10):2694–2698. doi:10.1093/annonc/mdt291.
   PubMed Web of Science ®Google Scholar
• Brunet J-F, Denizot F, Luciani M-F, Roux-Dosseto M, Suzan M, Mattei M-G, Golstein P. A new member of the immunoglobulin superfamily—CTLA-4. Nature. 1987;328(6127):267–270. doi:10.1038/328267a0.
   PubMed Web of Science ®Google Scholar
• Sansom DM. CD28, CTLA-4 and their ligands: who does what and to whom? Immunology. 2000;101(2):169–77. doi:10.1046/j.1365-2567.2000.00121.x.
   PubMed Web of Science ®Google Scholar
• Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol. 2002;3(7):611–8. doi:10.1038/ni0702-611.
   PubMed Web of Science ®Google Scholar
• Walker LSK, Sansom DM. Confusing signals: recent progress in CTLA-4 biology. Trends Immunol. 2015;36(2):63–70. doi:10.1016/j.it.2014.12.001.
   PubMed Web of Science ®Google Scholar
• Sansom DM, Walker LSK. The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol Rev. 2006;212(1):131–48. doi:10.1111/j.0105-2896.2006.00419.x.
   PubMedGoogle Scholar
• Hurst JH. Cancer immunotherapy innovator James Allison receives the 2015 Lasker~DeBakey clinical medical research award. J Clin Invest. 2015;125(10):3732–6. doi:10.1172/JCI84236.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen T-T, Berman DM, Wolchok JD, et al. Pooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–94. doi:10.1200/JCO.2014.56.2736.
   PubMed Web of Science ®Google Scholar
• Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of Indications of FDA-Approved immune checkpoint inhibitors per NCCN Guidelines With The Level Of Evidence. Cancers Basel. 2020;12(3):738. doi:10.3390/cancers12030738.
   PubMed Web of Science ®Google Scholar
• Dalle S, Mortier L, Corrie P, Lotem M, Board R, Arance AM, Meiss F, Terheyden P, Gutzmer R, Buysse B, et al. Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study. BMC Cancer. 2021;21(1):642. doi:10.1186/s12885-021-08032-y.
   PubMed Web of Science ®Google Scholar
• Cramer-van der Welle CM, Verschueren MV, Tonn M, Peters BJM, Schramel F, Klungel OH, Groen HJM, van de Garde EMW, Kastelijn EA, Vermeer LC, et al. Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands. Sci Rep. 2021;11(1):6306. doi:10.1038/s41598-021-85696-3.
   PubMedGoogle Scholar
• Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Lao CD, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–84. doi:10.1016/S1470-2045(15)70076-8.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D’Angelo SP, Shih KC, Lebbé C, Linette GP, Milella M, et al. Avelumab in patients with chemotherapy-refractory metastatic merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374–85. doi:10.1016/S1470-2045(16)30364-3.
   PubMed Web of Science ®Google Scholar
• Keilholz U, Mehnert JM, Bauer S, Bourgeois H, Patel MR, Gravenor D, Nemunaitis JJ, Taylor MH, Wyrwicz L, Lee K-W, et al. Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN solid tumor trial. J Immunother Cancer. 2019;7(1):12. doi:10.1186/s40425-018-0459-y.
   PubMed Web of Science ®Google Scholar
• Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, Curiel TJ, Colon-Otero G, Hamid O, Sanborn RE, et al. Safety and efficacy of durvalumab (MEDI4736), an anti–programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016;34(26):3119–3125. doi:10.1200/JCO.2016.67.9761.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. doi:10.1056/NEJMoa1003466.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. doi:10.1056/NEJMoa1504030.
   PubMed Web of Science ®Google Scholar
• Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390(10105):1853–62. doi:10.1016/S0140-6736(17)31601-X.
   PubMed Web of Science ®Google Scholar
• van Elsas MJ, van Hall T, van der Burg SH. Future challenges in cancer resistance to immunotherapy. Cancers Basel. 2020;12(4):935. doi:10.3390/cancers12040935.
   PubMed Web of Science ®Google Scholar
• Kluger HM, Tawbi HA, Ascierto ML, Bowden M, Callahan MK, Cha E, Chen HX, Drake CG, Feltquate DM, Ferris RL, et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC immunotherapy resistance taskforce. J Immunother Cancer. 2020;8(1):e000398. doi:10.1136/jitc-2019-000398.
   PubMed Web of Science ®Google Scholar
• De Martino M, Vanpouille-Box C, Galluzzi L. Immunological barriers to immunotherapy in primary and metastatic breast cancer. EMBO Mol Med. 2021;13(8):e14393. doi:10.15252/emmm.202114393.
   PubMed Web of Science ®Google Scholar
• Emens LA. Breast cancer immunotherapy: facts and hopes. Clin Cancer Res. 2018;24(3):511–20. doi:10.1158/1078-0432.CCR-16-3001.
   PubMed Web of Science ®Google Scholar
• Vukadin S, Khaznadar F, Kizivat T, Vcev A, Smolic M. Molecular mechanisms of resistance to immune checkpoint inhibitors in melanoma treatment: an update. Biomedicines. 2021;9(7):835. doi:10.3390/biomedicines9070835.
   PubMed Web of Science ®Google Scholar
• Boyero L, Sanchez-Gastaldo A, Alonso M, Noguera-Ucles JF, Molina-Pinelo S, Bernabe-Caro R. Primary and acquired resistance to immunotherapy in lung cancer: unveiling the mechanisms underlying of immune checkpoint blockade therapy. Cancers Basel. 2020;12(12):3729. doi:10.3390/cancers12123729.
   PubMed Web of Science ®Google Scholar
• Walsh RJ, Soo RA. Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies. Ther Adv Med Oncol. 2020;12:1758835920937902. doi:10.1177/1758835920937902.
   Web of Science ®Google Scholar
• Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct Target Ther. 2021;6(1):72. doi:10.1038/s41392-020-00449-4.
   PubMed Web of Science ®Google Scholar
• Fabian KP, Padget MR, Fujii R, Schlom J, Hodge JW. Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve. J Immunother Cancer. 2021;9(2):e001691. doi:10.1136/jitc-2020-001691.
   PubMed Web of Science ®Google Scholar
• Hicks KC, Chariou PL, Ozawa Y, Minnar CM, Knudson KM, Meyer TJ, Bian J, Cam M, Schlom J, Gameiro SR, et al. Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape. Nat Commun. 2021;12(1):5151. doi:10.1038/s41467-021-25393-x.
   PubMed Web of Science ®Google Scholar
• Horn LA, Chariou PL, Gameiro SR, Qin H, Iida M, Fousek K, Meyer TJ, Cam M, Flies D, Langermann S, et al. Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1–mediated tumor eradication. J Clin Invest. 2022;132(8). doi:10.1172/JCI155148.
   PubMed Web of Science ®Google Scholar
• Minnar CM, Chariou PL, Horn LA, Hicks KC, Palena C, Schlom J, Gameiro SR. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies. J Immunother Cancer. 2022;10(6):e004561. doi:10.1136/jitc-2022-004561.
   PubMed Web of Science ®Google Scholar
• Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med. 2013;210(7):1389–402. doi:10.1084/jem.20130066.
   PubMed Web of Science ®Google Scholar
• Franks SE, Santiago-Sanchez GS, Fabian KP, Solocinski K, Chariou PL, Hamilton DH, Kowalczyk JT, Padget MR, Gameiro SR, Schlom J, et al. Exploiting docetaxel-induced tumor cell necrosis with tumor targeted delivery of IL-12. Cancer Immunol Immunother. 2023;72(8):2783–2797. doi:10.1007/s00262-023-03459-7.
   PubMed Web of Science ®Google Scholar
• Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves Anti-PD-1 immunotherapy. Cell. 2017;170(6):1109–1119.e10. doi:10.1016/j.cell.2017.08.027.
   PubMed Web of Science ®Google Scholar
• Fabian KP, Malamas AS, Padget MR, Solocinski K, Wolfson B, Fujii R, Abdul Sater H, Schlom J, Hodge JW. Therapy of established tumors with rationally designed multiple agents targeting diverse immune–tumor interactions: engage, expand, enable. Cancer Immunol Res. 2021;9(2):239–252. doi:10.1158/2326-6066.CIR-20-0638.
   PubMed Web of Science ®Google Scholar
• Maleki Vareki S. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer. 2018;6(1):157. doi:10.1186/s40425-018-0479-7.
   PubMed Web of Science ®Google Scholar
• O’Donnell JS, Long GV, Scolyer RA, Teng MW, Smyth MJ. Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat Rev. 2017;52:71–81. doi:10.1016/j.ctrv.2016.11.007.
   PubMed Web of Science ®Google Scholar
• Sahin IH, Akce M, Alese O, Shaib W, Lesinski GB, El-Rayes B, Wu C. Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. Br J Cancer. 2019;121(10):809–818. doi:10.1038/s41416-019-0599-y.
   PubMed Web of Science ®Google Scholar
• Luciano S, Haudenschild C, Kuranz S. Using real world data to examine outcomes in immunotherapy-treated patients with metastatic non-small cell lung cancer. J Clin Oncol. 2020;38(15_suppl):e21715–e. doi:10.1200/JCO.2020.38.15_suppl.e21715.
   Google Scholar
• Miao K, Zhang X, Wang H, Si X, Ni J, Zhong W, Zhao J, Xu Y, Chen M, Pan R, et al. Real-world data of different immune checkpoint inhibitors for non-small cell lung cancer in China. Front Oncol. 2022;12:859938. doi:10.3389/fonc.2022.859938.
   PubMedGoogle Scholar
• Velcheti V, Hu X, Yang L, Pietanza MC, Burke T. Long-term real-world outcomes of first-line pembrolizumab monotherapy for metastatic non-small cell lung cancer with >/=50% expression of programmed cell death-ligand 1. Front Oncol. 2022;12:834761. doi:10.3389/fonc.2022.834761.
   PubMed Web of Science ®Google Scholar
• Kehl KL, Greenwald S, Chamoun NG, Manberg PJ, Schrag D. Association between first-line immune checkpoint inhibition and survival for medicare-insured patients with advanced non-small cell lung cancer. JAMA Netw Open. 2021;4(5):e2111113. doi:10.1001/jamanetworkopen.2021.11113.
   PubMed Web of Science ®Google Scholar
• Eroglu Z, Zaretsky JM, Hu-Lieskovan S, Kim DW, Algazi A, Johnson DB, Liniker E, Kong B, Munhoz R, Rapisuwon S, et al. High response rate to PD-1 blockade in desmoplastic melanomas. Nature. 2018;553(7688):347–50. doi:10.1038/nature25187.
   PubMed Web of Science ®Google Scholar
• Rose AAN, Armstrong SM, Hogg D, Butler MO, Saibil SD, Arteaga DP, Pimentel Muniz T, Kelly D, Ghazarian D, King I, et al. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy. J Immunother Cancer. 2021;9(1):e001642. doi:10.1136/jitc-2020-001642.
   PubMed Web of Science ®Google Scholar
• Stege HM, Haist M, Schultheis S, Fleischer MI, Mohr P, Ugurel S, Terheyden P, Thiem A, Kiecker F, Leiter U, et al. Response durability after cessation of immune checkpoint inhibitors in patients with metastatic merkel cell carcinoma: a retrospective multicenter DeCOG study. Cancer Immunol Immunother. 2021;70(11):3313–22. doi:10.1007/s00262-021-02925-4.
   PubMed Web of Science ®Google Scholar
• Zaggana E, Konstantinou MP, Krasagakis GH, de Bree E, Kalpakis K, Mavroudis D, Krasagakis K. Merkel Cell Carcinoma—Update on Diagnosis, Management and Future Perspectives. Cancers Basel. 2022;15(1):103. doi:10.3390/cancers15010103.
   PubMed Web of Science ®Google Scholar
• Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197–218. doi:10.1038/s41573-018-0007-y.
   PubMed Web of Science ®Google Scholar
• Duan Q, Zhang H, Zheng J, Zhang L. Turning cold into hot: firing up the tumor microenvironment. Trends Cancer. 2020;6(7):605–18. doi:10.1016/j.trecan.2020.02.022.
   PubMed Web of Science ®Google Scholar
• Knight A, Karapetyan L, Kirkwood JM. Immunotherapy in melanoma: recent advances and future directions. Cancers Basel. 2023;15(4):1106. doi:10.3390/cancers15041106.
   PubMed Web of Science ®Google Scholar
• LoPiccolo J, Schollenberger MD, Dakhil S, Rosner S, Ali O, Sharfman WH, Silk AW, Bhatia S, Lipson EJ. Rescue therapy for patients with anti-PD-1-refractory merkel cell carcinoma: a multicenter, retrospective case series. J Immunother Cancer. 2019;7(1):170. doi:10.1186/s40425-019-0661-6.
   PubMedGoogle Scholar
• Cowey CL, Mahnke L, Espirito J, Helwig C, Oksen D, Bharmal M. Real-world treatment outcomes in patients with metastatic merkel cell carcinoma treated with chemotherapy in the USA. Future Oncol. 2017;13(19):1699–1710. doi:10.2217/fon-2017-0187.
   PubMed Web of Science ®Google Scholar
• D’Angelo SP, Russell J, Lebbe C, Chmielowski B, Gambichler T, Grob JJ, Kiecker F, Rabinowits G, Terheyden P, Zwiener I, et al. Efficacy and safety of first-line avelumab treatment in patients with stage iv metastatic merkel cell carcinoma: a preplanned interim analysis of a clinical trial. JAMA Oncol. 2018;4(9):e180077. doi:10.1001/jamaoncol.2018.0077.
   PubMed Web of Science ®Google Scholar
• Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, et al. PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma. N Engl J Med. 2016;374(26):2542–52. doi:10.1056/NEJMoa1603702.
   PubMed Web of Science ®Google Scholar
• Weppler AM, Da Meda L, Pires da Silva I, Xu W, Grignani G, Menzies AM, Carlino MS, Long GV, Lo SN, Nordman I, et al. Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation. Eur J Cancer. 2023;183:109–18. doi:10.1016/j.ejca.2023.01.016.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. doi:10.1056/NEJMoa1606774.
   PubMed Web of Science ®Google Scholar
• Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, de Castro G Jr., Psyrri A, Basté N, Neupane P, Bratland Å, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915–1928. doi:10.1016/S0140-6736(19)32591-7.
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40. doi:10.1016/S0140-6736(21)00797-2.
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im S-A, Shaw Wright G, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018;379(22):2108–21. doi:10.1056/NEJMoa1809615.
   PubMed Web of Science ®Google Scholar
• Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, Kojima T, Metges J-P, Li Z, Kim S-B, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–71. doi:10.1016/S0140-6736(21)01234-4.
   PubMed Web of Science ®Google Scholar
• Garassino MC, Gadgeel S, Esteban E, Felip E, Speranza G, Domine M, Hochmair MJ, Powell S, Cheng SYS, Bischoff HG, et al. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(3):387–97. doi:10.1016/S1470-2045(19)30801-0.
   PubMed Web of Science ®Google Scholar
• Lanka SM, Zorko NA, Antonarakis ES, Barata PC. Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond. Curr Oncol. 2023;30(4):4246–4256. doi:10.3390/curroncol30040323.
   PubMed Web of Science ®Google Scholar
• Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N, et al. Evolution of neoantigen landscape during immune checkpoint blockade in non–small cell lung cancer. Cancer Discov. 2017;7(3):264–276. doi:10.1158/2159-8290.CD-16-0828.
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Sci. 2017;357(6349):409–13. doi:10.1126/science.aan6733.
   PubMed Web of Science ®Google Scholar
• Zhou B, Gao Y, Zhang P, Chu Q. Acquired resistance to immune checkpoint blockades: the underlying mechanisms and potential strategies. Front Immunol. 2021;12:693609. doi:10.3389/fimmu.2021.693609.
   PubMed Web of Science ®Google Scholar
• Schwartz LH, Litiere S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, et al. RECIST 1.1—update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132–137. doi:10.1016/j.ejca.2016.03.081.
   PubMed Web of Science ®Google Scholar
• Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–e152. doi:10.1016/S1470-2045(17)30074-8.
   PubMed Web of Science ®Google Scholar
• Ramon-Patino JL, Schmid S, Lau S, Seymour L, Gaudreau PO, Li JJN, Bradbury PA, Calvo E. iRECIST and atypical patterns of response to immuno-oncology drugs. J Immunother Cancer. 2022;10(6):e004849. doi:10.1136/jitc-2022-004849.
   PubMed Web of Science ®Google Scholar
• Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33(31):3541–3. doi:10.1200/JCO.2015.61.6870.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–20. doi:10.1158/1078-0432.CCR-09-1624.
   PubMed Web of Science ®Google Scholar
• Ma Y, Wang Q, Dong Q, Zhan L, Zhang J. How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy. Am J Cancer Res. 2019;9(8):1546–53.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016;34(13):1510–7. doi:10.1200/JCO.2015.64.0391.
   PubMed Web of Science ®Google Scholar
• Cai Y, Tian Y, Wang J, Wei W, Tang Q, Lu L, Luo Z, Li W, Lu Y, Pu J, et al. Identification of driver genes regulating the T-Cell–infiltrating levels in hepatocellular carcinoma. Front Genet. 2020;11:560546. doi:10.3389/fgene.2020.560546.
   PubMed Web of Science ®Google Scholar
• Wang H, Guo M, Wei H, Chen Y. Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduct Target Ther. 2023;8(1):92. doi:10.1038/s41392-023-01347-1.
   PubMed Web of Science ®Google Scholar
• Sprooten J, De Wijngaert P, Vanmeerbeerk I, Martin S, Vangheluwe P, Schlenner S, Krysko DV, Parys JB, Bultynck G, Vandenabeele P, et al. Necroptosis in immuno-oncology and cancer immunotherapy. Cells. 2020;9(8):1823. doi:10.3390/cells9081823.
   PubMed Web of Science ®Google Scholar
• Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 2018;118(1):9–16. doi:10.1038/bjc.2017.434.
   PubMed Web of Science ®Google Scholar
• Adachi K, Davis MM. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells. Proc Natl Acad Sci U S A. 2011;108(4):1549–1554. doi:10.1073/pnas.1017340108.
   PubMed Web of Science ®Google Scholar
• Ngan HL, Law CH, Choi YCY, Chan JY, Lui VWY. Precision drugging of the MAPK pathway in head and neck cancer. NPJ Genom Med. 2022;7(1):20. doi:10.1038/s41525-022-00293-1.
   PubMed Web of Science ®Google Scholar
• Ngan HL, Liu Y, Fong AY, Poon PHY, Yeung CK, Chan SSM, Lau A, Piao W, Li H, Tse JSW, et al. MAPK pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling. Life Sci Alli. 2020;3(6):e201900545. doi:10.26508/lsa.201900545.
   PubMed Web of Science ®Google Scholar
• Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, et al. Loss of PTEN promotes resistance to T cell–mediated immunotherapy. Cancer Discov. 2016;6(2):202–216. doi:10.1158/2159-8290.CD-15-0283.
   PubMed Web of Science ®Google Scholar
• Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature. 2015;523(7559):231–235. doi:10.1038/nature14404.
   PubMed Web of Science ®Google Scholar
• Tentler JJ, Lang J, Capasso A, Kim DJ, Benaim E, Lee YB, Eisen A, Bagby SM, Hartman SJ, Yacob BW, et al. RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast cancer. BMC Cancer. 2020;20(1):1063. doi:10.1186/s12885-020-07500-1.
   PubMed Web of Science ®Google Scholar
• Jorgovanovic D, Song M, Wang L, Zhang Y. Roles of IFN-γ in tumor progression and regression: a review. Biomark Res. 2020;8(1):49. doi:10.1186/s40364-020-00228-x.
   PubMed Web of Science ®Google Scholar
• Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell. 2016;167(2):397–404.e9. doi:10.1016/j.cell.2016.08.069.
   PubMed Web of Science ®Google Scholar
• Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819–29. doi:10.1056/NEJMoa1604958.
   PubMed Web of Science ®Google Scholar
• Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu W-J, Weber JS, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315(15):1600–9. doi:10.1001/jama.2016.4059.
   PubMed Web of Science ®Google Scholar
• Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. Annu Rev Immunol. 2013;31(1):443–73. doi:10.1146/annurev-immunol-032712-095910.
   PubMed Web of Science ®Google Scholar
• Mpakali A, Stratikos E. The role of antigen processing and presentation in cancer and the efficacy of immune checkpoint inhibitor immunotherapy. Cancers Basel. 2021;13(1):134. doi:10.3390/cancers13010134.
   PubMed Web of Science ®Google Scholar
• Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope FA. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov. 2020;10(12):1808–25. doi:10.1158/2159-8290.CD-20-0522.
   PubMed Web of Science ®Google Scholar
• Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39(2):154–73. doi:10.1016/j.ccell.2020.10.001.
   PubMed Web of Science ®Google Scholar
• Shao C, Li G, Huang L, Pruitt S, Castellanos E, Frampton G, Carson KR, Snow T, Singal G, Fabrizio D, et al. Prevalence of high tumor mutational burden and association with survival in patients with less common solid tumors. JAMA Netw Open. 2020;3(10):e2025109. doi:10.1001/jamanetworkopen.2020.25109.
   PubMed Web of Science ®Google Scholar
• Zheng M. Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better. J Immunother Cancer. 2022;10(1):e003087. doi:10.1136/jitc-2021-003087.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Wolchok JD, Schadendorf D, Larkin J, Long GV, Qian X, Saci A, Young TC, Srinivasan S, Chang H, et al. TMB and inflammatory gene expression associated with clinical outcomes following immunotherapy in advanced melanoma. Cancer Immunol Res. 2021;9(10):1202–1213. doi:10.1158/2326-6066.CIR-20-0983.
   PubMed Web of Science ®Google Scholar
• Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598–2608. doi:10.1158/1535-7163.MCT-17-0386.
   PubMed Web of Science ®Google Scholar
• Imamura T, Ashida R, Ohshima K, Uesaka K, Sugiura T, Ohgi K, Yamada M, Otsuka S, Hatakeyama K, Nagashima T, et al. Characterization of pancreatic cancer with ultra-low tumor mutational burden. Sci Rep. 2023;13(1):4359. doi:10.1038/s41598-023-31579-8.
   PubMed Web of Science ®Google Scholar
• Thomas R, Al-Khadairi G, Decock J. Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects. Front Oncol. 2020;10:600573. doi:10.3389/fonc.2020.600573.
   PubMed Web of Science ®Google Scholar
• ElTanbouly MA, Croteau W, Noelle RJ, Lines JL. VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity. Semin Immunol. 2019;42:101308. doi:10.1016/j.smim.2019.101308.
   PubMed Web of Science ®Google Scholar
• Kato S, Okamura R, Kumaki Y, Ikeda S, Nikanjam M, Eskander R, Goodman A, Lee S, Glenn ST, Dressman D, et al. Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. Oncoimmunology. 2020;9(1):1708065. doi:10.1080/2162402X.2019.1708065.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–61. doi:10.1016/j.ccell.2015.03.001.
   PubMed Web of Science ®Google Scholar
• Mulati K, Hamanishi J, Matsumura N, Chamoto K, Mise N, Abiko K, Baba T, Yamaguchi K, Horikawa N, Murakami R, et al. VISTA expressed in tumour cells regulates T cell function. Br J Cancer. 2019;120(1):115–27. doi:10.1038/s41416-018-0313-5.
   PubMed Web of Science ®Google Scholar
• Wang L, Rubinstein R, Lines JL, Wasiuk A, Ahonen C, Guo Y, Lu L-F, Gondek D, Wang Y, Fava RA, et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med. 2011;208(3):577–92. doi:10.1084/jem.20100619.
   PubMed Web of Science ®Google Scholar
• Kakavand H, Jackett LA, Menzies AM, Gide TN, Carlino MS, Saw RPM, Thompson JF, Wilmott JS, Long GV, Scolyer RA, et al. Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. Mod Pathol. 2017;30(12):1666–76. doi:10.1038/modpathol.2017.89.
   PubMed Web of Science ®Google Scholar
• Li HB, Yang ZH, Guo QQ. Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review. Cell Commun Signal. 2021;19(1):117. doi:10.1186/s12964-021-00789-w.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016;7(1):10582. doi:10.1038/ncomms10582.
   PubMedGoogle Scholar
• Johnson DB, Nixon MJ, Wang Y, Wang DY, Castellanos E, Estrada MV, Ericsson-Gonzalez PI, Cote CH, Salgado R, Sanchez V, et al. Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. JCI Insight. 2018;3(24). doi:10.1172/jci.insight.120360.
   Web of Science ®Google Scholar
• Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, Lele S, Shrikant P, et al. Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A. 2010;107(17):7875–7880. doi:10.1073/pnas.1003345107.
   PubMed Web of Science ®Google Scholar
• Andrews LP, Cillo AR, Karapetyan L, Kirkwood JM, Workman CJ, Vignali DAA. Molecular pathways and mechanisms of LAG3 in cancer therapy. Clin Cancer Res. 2022;28(23):5030–9. doi:10.1158/1078-0432.CCR-21-2390.
   PubMed Web of Science ®Google Scholar
• Draghi A, Chamberlain CA, Furness A, Donia M. Acquired resistance to cancer immunotherapy. Semin Immunopathol. 2019;41(1):31–40. doi:10.1007/s00281-018-0692-y.
   PubMed Web of Science ®Google Scholar
• Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7(1):10501. doi:10.1038/ncomms10501.
   PubMed Web of Science ®Google Scholar
• Shayan G, Srivastava R, Li J, Schmitt N, Kane LP, Ferris RL. Adaptive resistance to anti-PD1 therapy by tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer. Oncoimmunology. 2017;6(1):e1261779. doi:10.1080/2162402X.2016.1261779.
   PubMed Web of Science ®Google Scholar
• Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207(10):2187–94. doi:10.1084/jem.20100643.
   PubMed Web of Science ®Google Scholar
• Franks SE, Fabian KP, Santiago-Sanchez G, Wolfson B, Hodge JW. Immune targeting of three independent suppressive pathways (TIGIT, PD-L1, TGFbeta) provides significant antitumor efficacy in immune checkpoint resistant models. Oncoimmunology. 2022;11(1):2124666. doi:10.1080/2162402X.2022.2124666.
   PubMed Web of Science ®Google Scholar
• Ge Z, Peppelenbosch MP, Sprengers D, Kwekkeboom J. TIGIT, the next step towards successful combination immune checkpoint therapy in cancer. Front Immunol. 2021;12:699895. doi:10.3389/fimmu.2021.699895.
   PubMed Web of Science ®Google Scholar
• Kawashima S, Inozume T, Kawazu M, Ueno T, Nagasaki J, Tanji E, Honobe A, Ohnuma T, Kawamura T, Umeda Y, et al. TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment. J Immunother Cancer. 2021;9(11):e003134. doi:10.1136/jitc-2021-003134.
   PubMed Web of Science ®Google Scholar
• Freed-Pastor WA, Lambert LJ, Ely ZA, Pattada NB, Bhutkar A, Eng G, Mercer KL, Garcia AP, Lin L, Rideout WM, et al. The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Cancer Cell. 2021;39(10):1342–1360.e14. doi:10.1016/j.ccell.2021.07.007.
   PubMed Web of Science ®Google Scholar
• Zhulai G, Oleinik E. Targeting regulatory T cells in anti-PD-1/PD-L1 cancer immunotherapy. Scand J Immunol. 2022;95(3):e13129. doi:10.1111/sji.13129.
   PubMed Web of Science ®Google Scholar
• Batlle E, Massague J. Transforming growth factor-beta signaling in immunity and cancer. Immunity. 2019;50(4):924–940. doi:10.1016/j.immuni.2019.03.024.
   PubMed Web of Science ®Google Scholar
• Ni Y, Soliman A, Joehlin-Price A, Rose PG, Vlad A, Edwards RP, Mahdi H. High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition. Npj Precis Oncol. 2021;5(1):101. doi:10.1038/s41698-021-00242-8.
   PubMed Web of Science ®Google Scholar
• Martin CJ, Datta A, Littlefield C, Kalra A, Chapron C, Wawersik S, Dagbay KB, Brueckner CT, Nikiforov A, Danehy FT, et al. Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape. Sci Transl Med. 2020;12(536). doi:10.1126/scitranslmed.aay8456.
   Web of Science ®Google Scholar
• Siewe N, Friedman A, Najbauer J. TGF-β inhibition can overcome cancer primary resistance to PD-1 blockade: a mathematical model. PloS ONE. 2021;16(6):e0252620. doi:10.1371/journal.pone.0252620.
   PubMed Web of Science ®Google Scholar
• Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S. Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients? Am Soc Clin Oncol Educ Book. 2019;39(39):147–164. doi:10.1200/EDBK_240837.
   PubMedGoogle Scholar
• Zahavi D, Hodge JW. Targeting Immunosuppressive Adenosine Signaling: a Review of Potential Immunotherapy Combination Strategies. Int J Mol Sci. 2023;24(10):8871. doi:10.3390/ijms24108871.
   PubMed Web of Science ®Google Scholar
• Fujiwara Y, Kato S, Nesline MK, Conroy JM, DePietro P, Pabla S, Kurzrock R. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy. Cancer Treat Rev. 2022;110:102461. doi:10.1016/j.ctrv.2022.102461.
   PubMed Web of Science ®Google Scholar
• Beasley GM, Brown MC, Farrow NE, Landa K, Al-Rohil RN, Selim MA, Therien AD, Jung S-H, Gao J, Boczkowski D, et al. Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma. J Immunother Cancer. 2022;10(9):e005052. doi:10.1136/jitc-2022-005052.
   PubMed Web of Science ®Google Scholar
• Sullivan RJ, Gutierrez M, Khattak A, Thomas SS, Jimeno A, Pascarella S, Pascarella S, Zhu L, Morrissey M, Meehan RS, et al. Phase 1/2 study of mRNA-4359 administered alone and in combination with immune checkpoint blockade in adult participants with advanced solid tumors. J Clin Oncol. 2023;41(16_suppl):TPS2676–TPS. doi:10.1200/JCO.2023.41.16_suppl.TPS2676.
   Web of Science ®Google Scholar
• Jost M, Chen Y, Gilbert LA, Horlbeck MA, Krenning L, Menchon G, Rai A, Cho MY, Stern JJ, Prota AE, et al. Pharmaceutical-grade rigosertib is a microtubule-destabilizing agent. Mol Cell. 2020;79(1):191–198.e3. doi:10.1016/j.molcel.2020.06.008.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022;23(4):487–500. doi:10.1038/s41590-022-01132-2.
   PubMed Web of Science ®Google Scholar
• Fabian KP, Wolfson B, Hodge JW. From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment. Front Oncol. 2021;11:728018. doi:10.3389/fonc.2021.728018.
   PubMed Web of Science ®Google Scholar
• Fabian KP, Kowalczyk JT, Reynolds ST, Hodge JW. Dying of stress: chemotherapy, radiotherapy, and small-molecule inhibitors in immunogenic cell death and immunogenic modulation. Cells. 2022;11(23):3826. doi:10.3390/cells11233826.
   PubMed Web of Science ®Google Scholar
• Pfirschke C, Engblom C, Rickelt S, Cortez-Retamozo V, Garris C, Pucci F, Yamazaki T, Poirier-Colame V, Newton A, Redouane Y, et al. Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity. 2016;44(2):343–54. doi:10.1016/j.immuni.2015.11.024.
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Buqué A, Ames TD, Galluzzi L. PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models. OncoImmunology. 2020;9(1):1721810. doi:10.1080/2162402X.2020.1721810.
   PubMed Web of Science ®Google Scholar
• Zhou H, Tu C, Yang P, Li J, Kepp O, Li H, Zhang L, Zhang L, Zhao Y, Zhang T, et al. Carbon ion radiotherapy triggers immunogenic cell death and sensitizes melanoma to anti-PD-1 therapy in mice. Oncoimmunology. 2022;11(1):2057892. doi:10.1080/2162402X.2022.2057892.
   PubMed Web of Science ®Google Scholar
• Kepp O, Zitvogel L, Kroemer G. Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade. Oncoimmunology. 2019;8(10):e1637188. doi:10.1080/2162402X.2019.1637188.
   PubMed Web of Science ®Google Scholar
• Mansfield AS, Każarnowicz A, Karaseva N, Sánchez A, De Boer R, Andric Z, Reck M, Atagi S, Lee J-S, Garassino M, et al. Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial. Ann Oncol. 2020;31(2):310–7. doi:10.1016/j.annonc.2019.10.021.
   PubMed Web of Science ®Google Scholar
• Røssevold AH, Andresen NK, Bjerre CA, Gilje B, Jakobsen EH, Raj SX, Falk RS, Russnes HG, Jahr T, Mathiesen RR, et al. Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial. Nat Med. 2022;28(12):2573–83. doi:10.1038/s41591-022-02126-1.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Sci. 2015;348(6230):62–8. doi:10.1126/science.aaa4967.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550–7. doi:10.1158/1078-0432.CCR-11-0116.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Jiang Y, Xiang S, Kaboli PJ, Shen J, Zhao Y, Wu X, Du F, Li M, Cho CH, et al. Engineered TCR-T cell immunotherapy in anticancer precision medicine: pros and cons. Front Immunol. 2021;12:12. doi:10.3389/fimmu.2021.658753.
   Web of Science ®Google Scholar
• Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, et al. NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015;21(8):914–21. doi:10.1038/nm.3910.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917–24. doi:10.1200/JCO.2010.32.2537.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1–reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21(5):1019–1027. doi:10.1158/1078-0432.CCR-14-2708.
   PubMed Web of Science ®Google Scholar
• Moon EK, Ranganathan R, Eruslanov E, Kim S, Newick K, O’Brien S, Lo A, Liu X, Zhao Y, Albelda SM, et al. Blockade of programmed death 1 augments the ability of human t cells engineered to target NY-ESO-1 to control tumor growth after adoptive transfer. Clin Cancer Res. 2016;22(2):436–47. doi:10.1158/1078-0432.CCR-15-1070.
   PubMed Web of Science ®Google Scholar
• Martinez M, Kim S, St Jean N, O’Brien S, Lian L, Sun J, Verona RI, Moon E. Addition of anti-TIM3 or anti-TIGIT antibodies to anti-PD1 blockade augments human T cell adoptive cell transfer. Oncoimmunology. 2021;10(1):1873607. doi:10.1080/2162402X.2021.1873607.
   PubMed Web of Science ®Google Scholar
• Nowicki TS, Berent-Maoz B, Cheung-Lau G, Huang RR, Wang X, Tsoi J, Kaplan-Lefko P, Cabrera P, Tran J, Pang J, et al. A pilot trial of the combination of transgenic NY-ESO-1–reactive adoptive cellular therapy with dendritic cell vaccination with or without ipilimumab. Clin Cancer Res. 2019;25(7):2096–108. doi:10.1158/1078-0432.CCR-18-3496.
   PubMed Web of Science ®Google Scholar
• Rossetti R, Brand H, Lima SCG, Furtado IP, Silveira RM, Fantacini DMC, Covas DT, de Souza LEB. Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer. Immunol Adv. 2022;2(1):ltac005. doi:10.1093/immadv/ltac005.
   Google Scholar
• Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol. 2023;14:1188049. doi:10.3389/fimmu.2023.1188049.
   PubMed Web of Science ®Google Scholar
• Marofi F, Motavalli R, Safonov VA, Thangavelu L, Yumashev AV, Alexander M, Shomali N, Chartrand MS, Pathak Y, Jarahian M, et al. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res Ther. 2021;12(1):81. doi:10.1186/s13287-020-02128-1.
   PubMed Web of Science ®Google Scholar
• McGowan E, Lin Q, Ma G, Yin H, Chen S, Lin Y. PD-1 disrupted CAR-T cells in the treatment of solid tumors: promises and challenges. Biomed Pharmacother. 2020;121:109625. doi:10.1016/j.biopha.2019.109625.
   PubMed Web of Science ®Google Scholar
• Xu Y, Chen C, Guo Y, Hu S, Sun Z. 2022. Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy. Front Immunol. 13:848327. 10.3389/fimmu.2022.848327.
   PubMed Web of Science ®Google Scholar
• Ott PA, Wu CJ. Cancer vaccines: steering T cells down the right path to eradicate tumors. Cancer Discov. 2019;9(4):476–81. doi:10.1158/2159-8290.CD-18-1357.
   PubMed Web of Science ®Google Scholar
• Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018;18(3):168–82. doi:10.1038/nri.2017.131.
   PubMed Web of Science ®Google Scholar
• Wolfson B, Franks SE, Hodge JW. Stay on target: reengaging cancer vaccines in combination immunotherapy. Vaccines (Basel). 2021;9(5):509. doi:10.3390/vaccines9050509.
   PubMed Web of Science ®Google Scholar
• Sahin U, Oehm P, Derhovanessian E, Jabulowsky RA, Vormehr M, Gold M, Maurus D, Schwarck-Kokarakis D, Kuhn AN, Omokoko T, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020;585(7823):107–12. doi:10.1038/s41586-020-2537-9.
   PubMed Web of Science ®Google Scholar
• Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002;13(2):155–68. doi:10.1016/S1359-6101(01)00032-6.
   PubMed Web of Science ®Google Scholar
• Mirlekar B, Pylayeva-Gupta Y. IL-12 family cytokines in cancer and immunotherapy. Cancers Basel. 2021;13(2):167. doi:10.3390/cancers13020167.
   PubMed Web of Science ®Google Scholar
• Tugues S, Burkhard SH, Ohs I, Vrohlings M, Nussbaum K, Vom Berg J, Kulig P, Becher B. New insights into IL-12-mediated tumor suppression. Cell Death Differ. 2015;22(2):237–246. doi:10.1038/cdd.2014.134.
   PubMed Web of Science ®Google Scholar
• Vom Berg J, Vrohlings M, Haller S, Haimovici A, Kulig P, Sledzinska A, Weller M, Becher B. Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection. J Exp Med. 2013;210(13):2803–2811. doi:10.1084/jem.20130678.
   PubMed Web of Science ®Google Scholar
• Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol. 2006;6(8):595–601. doi:10.1038/nri1901.
   PubMed Web of Science ®Google Scholar
• Waldmann TA, Dubois S, Miljkovic MD, Conlon KC. IL-15 in the combination immunotherapy of cancer. Front Immunol. 2020;11:11. doi:10.3389/fimmu.2020.00868.
   PubMedGoogle Scholar
• Robinson TO, Schluns KS. The potential and promise of IL-15 in immuno-oncogenic therapies. Immunol Lett. 2017;190:159–68. doi:10.1016/j.imlet.2017.08.010.
   PubMed Web of Science ®Google Scholar
• Yu P, Steel JC, Zhang M, Morris JC, Waldmann TA. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin Cancer Res. 2010;16(24):6019–28. doi:10.1158/1078-0432.CCR-10-1966.
   PubMed Web of Science ®Google Scholar
• Yu P, Steel JC, Zhang M, Morris JC, Waitz R, Fasso M, Allison JP, Waldmann TA. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Proc Natl Acad Sci USA. 2012;109(16):6187–6192. doi:10.1073/pnas.1203479109.
   PubMed Web of Science ®Google Scholar
• Lui G, Minnar CM, Soon-Shiong P, Schlom J, Gameiro SR. Exploiting an interleukin-15 heterodimeric agonist (n803) for effective immunotherapy of solid malignancies. Cells. 2023;12(12):1611. doi:10.3390/cells12121611.
   PubMed Web of Science ®Google Scholar
• Knudson KM, Hicks KC, Alter S, Schlom J, Gameiro SR. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy. J Immunother Cancer. 2019;7(1):82. doi:10.1186/s40425-019-0551-y.
   PubMedGoogle Scholar
• Fabian KP, Padget MR, Donahue RN, Solocinski K, Robbins Y, Allen CT, Lee JH, Rabizadeh S, Soon-Shiong P, Schlom J, et al. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations. J Immunother Cancer. 2020;8(1):e000450. doi:10.1136/jitc-2019-000450.
   PubMed Web of Science ®Google Scholar
• Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, Miller JS, Farhad M, Anderton K, Lindsey K, et al. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018;19(5):694–704. doi:10.1016/S1470-2045(18)30148-7.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg Robert A. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, Lal P, Feldman MD, Benencia F, Coukos G, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20(6):607–15. doi:10.1038/nm.3541.
   PubMed Web of Science ®Google Scholar
• Patel SA, Nilsson MB, Le X, Cascone T, Jain RK, Heymach JV. Molecular mechanisms and future implications of VEGF/VEGFR in cancer therapy. Clin Cancer Res. 2023;29(1):30–9. doi:10.1158/1078-0432.CCR-22-1366.
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42. doi:10.1056/NEJMoa032691.
   PubMed Web of Science ®Google Scholar
• Botrel TEA, Clark L, Paladini L, Clark OAC. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer. 2016;16(1):677. doi:10.1186/s12885-016-2734-y.
   PubMedGoogle Scholar
• Liu Z-L, Chen H-H, Zheng L-L, Sun L-P, Shi L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Sig Transduct Target Ther. 2023;8(1):198. doi:10.1038/s41392-023-01460-1.
   PubMed Web of Science ®Google Scholar
• Du Four S, Maenhout SK, Niclou SP, Thielemans K, Neyns B, Aerts JL. Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs. Am J Cancer Res. 2016;6(11):2514–2531. doi:10.1080/2162402X.2014.998107.
   PubMed Web of Science ®Google Scholar
• Schmittnaegel M, Rigamonti N, Kadioglu E, Cassará A, Wyser Rmili C, Kiialainen A, Kienast Y, Mueller H-J, Ooi C-H, Laoui D, et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med. 2017;9(385):eaak9670. doi:10.1126/scitranslmed.aak9670.
   PubMed Web of Science ®Google Scholar
• Di Tacchio M, Macas J, Weissenberger J, Sommer K, Bähr O, Steinbach JP, Senft C, Seifert V, Glas M, Herrlinger U, et al. Tumor vessel normalization, immunostimulatory reprogramming, and improved survival in glioblastoma with combined inhibition of PD-1, angiopoietin-2, and VEGF. Cancer Immunol Res. 2019;7(12):1910–27. doi:10.1158/2326-6066.CIR-18-0865.
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, Kudo M, Breder V, Merle P, Kaseb AO, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–905. doi:10.1056/NEJMoa1915745.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862–73. doi:10.1016/j.jhep.2021.11.030.
   PubMed Web of Science ®Google Scholar
• Koh B, Tan DJH, Lim WH, Wong JSL, Ng CH, Chan KE, Wang M, Yong WP, Dan YY, Wang LZ, et al. Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma. OncoImmunology. 2023;12(1):2214478. doi:10.1080/2162402X.2023.2214478.
   PubMed Web of Science ®Google Scholar
• Lee MS, Ryoo B-Y, Hsu C-H, Numata K, Stein S, Verret W, Hack SP, Spahn J, Liu B, Abdullah H, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21(6):808–20. doi:10.1016/S1470-2045(20)30156-X.
   PubMed Web of Science ®Google Scholar
• Rygiel TP, Stolte EH, de Ruiter T, van de Weijer ML, Meyaard L. Tumor-expressed collagens can modulate immune cell function through the inhibitory collagen receptor LAIR-1. Mol Immunol. 2011;49(1–2):402–406. doi:10.1016/j.molimm.2011.09.006.
   PubMed Web of Science ®Google Scholar
• Carvalheiro T, Garcia S, Pascoal Ramos MI, Giovannone B, Radstake TRDJ, Marut W, Meyaard L. Leukocyte Associated Immunoglobulin Like Receptor 1 Regulation and Function on Monocytes and Dendritic Cells During Inflammation. Front Immunol. 2020;11:11. doi:10.3389/fimmu.2020.01793.
   PubMed Web of Science ®Google Scholar
• Ramos MIP, Tian L, de Ruiter EJ, Song C, Paucarmayta A, Singh A, Elshof E, Vijver SV, Shaik J, Bosiacki J, et al. Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction. eLife. 2021;10:e62927. doi:10.7554/eLife.62927.
   PubMed Web of Science ®Google Scholar
• Santiago-Sánchez GS, Hodge JW, Fabian KP. 2022. Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation. Front Immunol. 13. 10.3389/fimmu.2022.993624.
   PubMed Web of Science ®Google Scholar
• Tie Y, Tang F, Wei Y-Q, Wei X-W. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets. J Hematol Oncol. 2022;15(1):61. doi:10.1186/s13045-022-01282-8.
   PubMed Web of Science ®Google Scholar
• Burkholder B, Huang R-Y, Burgess R, Luo S, Jones VS, Zhang W, Lv Z-Q, Gao C-Y, Wang B-L, Zhang Y-M, et al. Tumor-induced perturbations of cytokines and immune cell networks. Biochimica Et Biophysica Acta (BBA) - Rev Cancer. 2014;1845(2):182–201. doi:10.1016/j.bbcan.2014.01.004.
   PubMed Web of Science ®Google Scholar
• Fultang L, Panetti S, Ng M, Collins P, Graef S, Rizkalla N, Booth S, Lenton R, Noyvert B, Shannon-Lowe C, et al. MDSC targeting with gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers. EBioMedicine. 2019;47:235–46. doi:10.1016/j.ebiom.2019.08.025.
   PubMed Web of Science ®Google Scholar
• Dominguez GA, Condamine T, Mony S, Hashimoto A, Wang F, Liu Q, Forero A, Bendell J, Witt R, Hockstein N, et al. Selective targeting of myeloid-derived suppressor cells in cancer patients using DS-8273a, an agonistic TRAIL-R2 antibody. Clin Cancer Res. 2017;23(12):2942–50. doi:10.1158/1078-0432.CCR-16-1784.
   PubMed Web of Science ®Google Scholar
• Eksioglu EA, Chen X, Heider KH, Rueter B, McGraw KL, Basiorka AA, Wei M, Burnette A, Cheng P, Lancet J, et al. Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858. Leukemia. 2017;31(10):2172–80. doi:10.1038/leu.2017.21.
   PubMed Web of Science ®Google Scholar
• Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov. 2018;17(12):887–904. doi:10.1038/nrd.2018.169.
   PubMed Web of Science ®Google Scholar
• Georgoudaki A-M, Prokopec Kajsa K, Boura Vanessa V, Hellqvist E, Sohn S, Östling J, Dahan R, Harris R, Rantalainen M, Klevebring D, et al. Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep. 2016;15(9):2000–2011. doi:10.1016/j.celrep.2016.04.084.
   PubMed Web of Science ®Google Scholar
• Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R, Georgiou A, Sledzinska A, et al. Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors. Immunity. 2017;46(4):577–86. doi:10.1016/j.immuni.2017.03.013.
   PubMed Web of Science ®Google Scholar
• Mitsui J, Nishikawa H, Muraoka D, Wang L, Noguchi T, Sato E, Kondo S, Allison JP, Sakaguchi S, Old LJ, et al. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin Cancer Res. 2010;16(10):2781–91. doi:10.1158/1078-0432.CCR-09-3243.
   PubMed Web of Science ®Google Scholar
• Ueha S, Yokochi S, Ishiwata Y, Ogiwara H, Chand K, Nakajima T, Hachiga K, Shichino S, Terashima Y, Toda E, et al. Robust antitumor effects of combined anti–CD4-Depleting antibody and anti–PD-1/PD-L1 immune checkpoint antibody treatment in mice. Cancer Immunol Res. 2015;3(6):631–640. doi:10.1158/2326-6066.CIR-14-0190.
   PubMed Web of Science ®Google Scholar
• Geva R, Voskoboynik M, Dobrenkov K, Mayawala K, Gwo J, Wnek R, Chartash E, Long GV. First-in-human phase 1 study of MK-1248, an anti–glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors. Cancer. 2020;126(22):4926–4935. doi:10.1002/cncr.33133.
   PubMed Web of Science ®Google Scholar
• Papadopoulos KP, Autio K, Golan T, Dobrenkov K, Chartash E, Chen Q, Wnek R, Long GV. Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors. Clin Cancer Res. 2021;27(7):1904–1911. doi:10.1158/1078-0432.CCR-20-2886.
   PubMed Web of Science ®Google Scholar
• Davar D, Zappasodi R, Wang H, Naik GS, Sato T, Bauer T, Bajor D, Rixe O, Newman W, Qi J, et al. Phase IB study of GITR agonist antibody TRX518 singly and in combination with gemcitabine, pembrolizumab, or nivolumab in patients with advanced solid tumors. Clin Cancer Res. 2022;28(18):3990–4002. doi:10.1158/1078-0432.CCR-22-0339.
   PubMed Web of Science ®Google Scholar
• Hernandez-Guerrero T, Moreno V. GITR antibodies in cancer: not ready for prime time. Clin Cancer Res. 2022;28(18):3905–7. doi:10.1158/1078-0432.CCR-22-1489.
   PubMed Web of Science ®Google Scholar
• Steele CW, Karim SA, Leach JDG, Bailey P, Upstill-Goddard R, Rishi L, Foth M, Bryson S, McDaid K, Wilson Z, et al. CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell. 2016;29(6):832–45. doi:10.1016/j.ccell.2016.04.014.
   PubMed Web of Science ®Google Scholar
• Greene S, Robbins Y, Mydlarz WK, Huynh AP, Schmitt NC, Friedman J, Horn LA, Palena C, Schlom J, Maeda DY, et al. Inhibition of MDSC trafficking with SX-682, a CXCR1/2 inhibitor, enhances NK-Cell immunotherapy in head and neck cancer models. Clin Cancer Res. 2020;26(6):1420–31. doi:10.1158/1078-0432.CCR-19-2625.
   PubMed Web of Science ®Google Scholar
• Horn LA, Riskin J, Hempel HA, Fousek K, Lind H, Hamilton DH, McCampbell KK, Maeda DY, Zebala JA, Su Z, et al. Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity. J Immunother Cancer. 2020;8(1):e000326. doi:10.1136/jitc-2019-000326.
   PubMed Web of Science ®Google Scholar
• Nywening TM, Belt BA, Cullinan DR, Panni RZ, Han BJ, Sanford DE, Jacobs RC, Ye J, Patel AA, Gillanders WE, et al. Targeting both tumour-associated CXCR2+neutrophils and CCR2+macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. Gut. 2018;67(6):1112–1123. doi:10.1136/gutjnl-2017-313738.
   PubMed Web of Science ®Google Scholar
• Hornyák L, Dobos N, Koncz G, Karányi Z, Páll D, Szabó Z, Halmos G, Székvölgyi L. The role of indoleamine-2,3-dioxygenase in cancer development, diagnostics, and therapy. Front Immunol. 2018;9:151. doi:10.3389/fimmu.2018.00151.
   PubMed Web of Science ®Google Scholar
• Abd El-Fattah EE. Ido/kynurenine pathway in cancer: possible therapeutic approaches. J Transl Med. 2022;20(1):347. doi:10.1186/s12967-022-03554-w.
   PubMed Web of Science ®Google Scholar
• Yao Y, Liang H, Fang X, Zhang S, Xing Z, Shi L, Kuang C, Seliger B, Yang Q. What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past. J Exp Clin Canc Res. 2021;40(1):60. doi:10.1186/s13046-021-01847-4.
   PubMed Web of Science ®Google Scholar
• Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, Arance A, Carlino MS, Grob J-J, Kim TM, et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 2019;20(8):1083–97. doi:10.1016/S1470-2045(19)30274-8.
   PubMed Web of Science ®Google Scholar
• Robert DL, Leisha AE. Targeting adenosine for cancer immunotherapy. J Immunother Cancer. 2018;6(1):57. doi:10.1186/s40425-018-0360-8.
   PubMedGoogle Scholar
• Thomas DA, Massagué J. TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell. 2005;8(5):369–80. doi:10.1016/j.ccr.2005.10.012.
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh M, Rosenberg SA. TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J Immunol. 2005;174(9):5215–5223. doi:10.4049/jimmunol.174.9.5215.
   PubMed Web of Science ®Google Scholar
• Gunderson AJ, Yamazaki T, McCarty K, Fox N, Phillips M, Alice A, Blair T, Whiteford M, O’Brien D, Ahmad R, et al. TGFβ suppresses CD8+ T cell expression of CXCR3 and tumor trafficking. Nat Commun. 2020;11(1):1749. doi:10.1038/s41467-020-15404-8.
   PubMed Web of Science ®Google Scholar
• Batlle E, Massagué J. Transforming growth factor-β signaling in immunity and cancer. Immunity. 2019;50(4):924–40. doi:10.1016/j.immuni.2019.03.024.
   PubMed Web of Science ®Google Scholar
• Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer. 2020;20(9):485–503. doi:10.1038/s41568-020-0281-y.
   PubMed Web of Science ®Google Scholar
• Lan Y, Zhang D, Xu C, Hance KW, Marelli B, Qi J, Yu H, Qin G, Sircar A, Hernández VM, et al. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β. Sci Transl Med. 2018;10(424). doi:10.1126/scitranslmed.aan5488.
   PubMed Web of Science ®Google Scholar
• Knudson KM, Hicks KC, Luo X, Chen JQ, Schlom J, Gameiro SR. M7824, a novel bifunctional anti-PD-L1/TGFβ trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. Oncoimmunology. 2018;7(5):e1426519. doi:10.1080/2162402X.2018.1426519.
   PubMed Web of Science ®Google Scholar
• Gameiro SR, Strauss J, Gulley JL, Schlom J. Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFβRII agent: Current status. Exp Biol Med (Maywood). 2022;247(13):1124–34. doi:10.1177/15353702221089910.
   PubMed Web of Science ®Google Scholar